Published in J Mol Med (Berl) on January 20, 2013
Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov (2015) 1.12
The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front Immunol (2013) 1.06
Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res (2014) 1.01
Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies. Front Immunol (2013) 0.86
Extracellular adenosine signaling in molecular medicine. J Mol Med (Berl) (2013) 0.86
NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model. Cells (2015) 0.80
Growth and metastasis of B16-F10 melanoma cells is not critically dependent on host CD73 expression in mice. BMC Cancer (2014) 0.79
Hypoxia-Inducible Factor-2α Limits Natural Killer T Cell Cytotoxicity in Renal Ischemia/Reperfusion Injury. J Am Soc Nephrol (2015) 0.77
Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma. Mol Med (2016) 0.77
Mutation in the Drosophila melanogaster adenosine receptor gene selectively decreases the mosaic hyperplastic epithelial outgrowth rates in wts or dco heterozygous flies. Purinergic Signal (2014) 0.75
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature (2002) 6.50
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44
Adenosine receptors as therapeutic targets. Nat Rev Drug Discov (2006) 6.15
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol (2004) 4.28
A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A (2006) 4.25
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev (2011) 4.16
Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol (2001) 3.75
Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. Nat Rev Immunol (2005) 3.21
CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat Med (2002) 3.18
Physiological roles for ecto-5'-nucleotidase (CD73). Purinergic Signal (2006) 2.98
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A (2010) 2.67
Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood (1997) 2.67
The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest (1993) 2.66
Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med (2006) 2.62
HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak. Blood (2008) 2.52
HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB J (2006) 2.46
The 'danger' sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol (2005) 2.43
Cellular and humoral immunity to different types of human neoplasms. Nature (1968) 2.40
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J Immunol (2005) 2.37
Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol (2005) 2.36
Seven transmembrane receptors: something old, something new. Acta Physiol (Oxf) (2007) 2.25
Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest (2003) 2.22
Hypoxia modulates adenosine receptors in human endothelial and smooth muscle cells toward an A2B angiogenic phenotype. Hypertension (2004) 2.18
CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res (2010) 2.13
The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. J Clin Invest (1990) 2.12
Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther (2008) 2.07
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res (2011) 2.03
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev (2011) 2.02
Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest (2011) 2.01
Dendritic cells tolerized with adenosine A₂AR agonist attenuate acute kidney injury. J Clin Invest (2012) 2.00
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98
The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res (1997) 1.95
Selective inactivation or reconstitution of adenosine A2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nat Med (2004) 1.93
Adenosine receptors in regulation of dendritic cell differentiation and function. Blood (2008) 1.91
Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res (2008) 1.84
Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J Exp Med (2001) 1.79
Memory of extracellular adenosine A2A purinergic receptor-mediated signaling in murine T cells. J Biol Chem (1997) 1.76
Wound healing is accelerated by agonists of adenosine A2 (G alpha s-linked) receptors. J Exp Med (1997) 1.75
Cellular constituents of immune escape within the tumor microenvironment. Cancer Res (2012) 1.75
From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc Natl Acad Sci U S A (2009) 1.75
T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol (2009) 1.74
CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology (2010) 1.69
Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ Res (1997) 1.67
Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A (1991) 1.61
Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci U S A (2008) 1.60
Monoclonal TCR-redirected tumor cell killing. Nat Med (2012) 1.57
Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. J Immunol (2000) 1.54
CD73: a novel target for cancer immunotherapy. Cancer Res (2010) 1.52
CD73: a potent suppressor of antitumor immune responses. Trends Immunol (2012) 1.52
Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice. Biochem J (2001) 1.49
Adjuvants for cancer vaccines. Semin Immunol (2010) 1.48
Hypoxia-inducible factor-1α-dependent protection from intestinal ischemia/reperfusion injury involves ecto-5'-nucleotidase (CD73) and the A2B adenosine receptor. J Immunol (2011) 1.48
Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother (2012) 1.47
Cutting edge: Physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J Immunol (2004) 1.45
Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood (2002) 1.44
Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia (2008) 1.43
Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum (2003) 1.41
CD73-deficient mice are resistant to carcinogenesis. Cancer Res (2012) 1.38
Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol (2003) 1.38
Therapeutic cancer vaccines. Curr Opin Immunol (2006) 1.33
The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol (2009) 1.32
Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol (2008) 1.30
Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol (2011) 1.28
A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol (2009) 1.27
Adenosine receptors as drug targets. Exp Cell Res (2010) 1.27
Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol (2005) 1.26
Adenosine up-regulates cyclooxygenase-2 in human granulocytes: impact on the balance of eicosanoid generation. J Immunol (2002) 1.24
Hypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues. Cancer Metastasis Rev (2007) 1.21
Enhanced protection from renal ischemia-reperfusion [correction of ischemia:reperfusion] injury with A(2A)-adenosine receptor activation and PDE 4 inhibition. Kidney Int (2001) 1.20
Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling. Cancer Res (2007) 1.20
The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol (2012) 1.18
Aspects of the general biology of adenosine A2A signaling. Prog Neurobiol (2007) 1.17
Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother (2011) 1.16
Potentiation of neutrophil cyclooxygenase-2 by adenosine: an early anti-inflammatory signal. J Cell Sci (2005) 1.13
Adenosine acts through an A3 receptor to prevent the induction of murine anti-CD3-activated killer T cells. Int J Cancer (2002) 1.12
Novel investigational adenosine A2A receptor antagonists for Parkinson's disease. Expert Opin Investig Drugs (2009) 1.09
Physiological roles of A1 and A2A adenosine receptors in regulating heart rate, body temperature, and locomotion as revealed using knockout mice and caffeine. Am J Physiol Heart Circ Physiol (2009) 1.08
Interplay of hypoxia and A2B adenosine receptors in tissue protection. Adv Pharmacol (2011) 1.07
Locus of inhibitory action of cAMP-dependent protein kinase in the antigen receptor-triggered cytotoxic T lymphocyte activation pathway. J Biol Chem (1988) 1.06
Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology (2002) 1.05
Adora2b adenosine receptor engagement enhances regulatory T cell abundance during endotoxin-induced pulmonary inflammation. PLoS One (2012) 1.05
A dialogue between the hypoxia-inducible factor and the tumor microenvironment. Cancer Microenviron (2008) 0.98
The A2aR adenosine receptor controls cytokine production in iNKT cells. Eur J Immunol (2010) 0.96
Adenosine receptors in wound healing, fibrosis and angiogenesis. Handb Exp Pharmacol (2009) 0.94
Potential use of an antagonist of cAMP-dependent protein kinase to block inhibition and modulate T-cell receptor-triggered activation of cytotoxic T-lymphocytes. J Pharm Sci (1989) 0.93
Effects of extracellular ATP and adenosine on different thymocyte subsets: possible role of ATP-gated channels and G protein-coupled purinergic receptor. J Immunol (1997) 0.92
Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease. Ann Neurol (2012) 0.91
In vitro induction of T cells that are resistant to A2 adenosine receptor-mediated immunosuppression. Br J Pharmacol (2008) 0.91
Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling. Immunology (2009) 0.90
Adenosine A2A agonist reduces paralysis after spinal cord ischemia: correlation with A2A receptor expression on motor neurons. Ann Thorac Surg (2002) 0.88
Adenosine as a possible inhibitor of killer T-cell activation in the microenvironment of solid tumours. Int J Cancer (1994) 0.88
Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. Clin Cancer Res (2008) 0.87
Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy. J Reprod Immunol (2002) 0.86
Immunology. Global or directed exocytosis? Nature (1988) 0.83
Damage control by hypoxia-inhibited AK. Blood (2008) 0.83
Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol (2004) 4.28
The 'danger' sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol (2005) 2.43
Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol (2005) 2.36
Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. J Immunol (2006) 1.93
Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res (2008) 1.84
Targeted deletion of HIF-1alpha gene in T cells prevents their inhibition in hypoxic inflamed tissues and improves septic mice survival. PLoS One (2007) 1.61
Cutting edge: Physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J Immunol (2004) 1.45
A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice. J Immunol (2011) 1.36
Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM). Endocr J (2009) 1.20
Analysis of A2a receptor-deficient mice reveals no significant compensatory increases in the expression of A2b, A1, and A3 adenosine receptors in lymphoid organs. Biochem Pharmacol (2003) 1.14
Critical role of hypoxia and A2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway. Mol Med (2008) 0.96
The A2aR adenosine receptor controls cytokine production in iNKT cells. Eur J Immunol (2010) 0.96
Prenatal and Postnatal Epigenetic Programming: Implications for GI, Immune, and Neuronal Function in Autism. Autism Res Treat (2012) 0.94
Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection. J Mol Med (Berl) (2014) 0.94
In vivo hypoxic preconditioning protects from warm liver ischemia-reperfusion injury through the adenosine A2B receptor. Transplantation (2012) 0.90
From "Hellstrom Paradox" to anti-adenosinergic cancer immunotherapy. Purinergic Signal (2007) 0.90
The antihypoxia-adenosinergic pathogenesis as a result of collateral damage by overactive immune cells. J Leukoc Biol (2009) 0.90
Comparison between shorter straight and thinner microtapered insulin injection needles. Diabetes Technol Ther (2013) 0.87
Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients. Endocr J (2007) 0.85
Comparison of Fenestra VC Contrast-enhanced computed tomography imaging with gadopentetate dimeglumine and ferucarbotran magnetic resonance imaging for the in vivo evaluation of murine liver damage after ischemia and reperfusion. Invest Radiol (2008) 0.83
Targeting hypoxia--A(2A) adenosine receptor-mediated mechanisms of tissue protection. Drug Discov Today (2004) 0.83
Postoperative hyperoxia (60%) worsens hepatic injury in mice. Anesthesiology (2014) 0.83
Serum free testosterone and metabolic syndrome in Japanese men. Endocr J (2010) 0.81
Genetic deletion of the HIF-1α isoform I.1 in T cells enhances antibacterial immunity and improves survival in a murine peritonitis model. Eur J Immunol (2013) 0.79
No ghrelin response to oral glucose in diabetes mellitus with gastroparesis. Endocr J (2008) 0.77
Synthesis of organic-inorganic hybrid bicelles-lipid bilayer nanodiscs encompassed by siloxane surfaces. Chem Commun (Camb) (2011) 0.76
Extracellular adenosine controls NKT-cell-dependent hepatitis induction. Eur J Immunol (2014) 0.75
Degree of micelle ionization and micellar growth for gemini surfactants detected by 6-methoxy-N-(3-sulfopropyl)quinolinium fluorescence quenching. Langmuir (2005) 0.75
Aqueous solution behavior of cationic surfactants containing sulfide linked alkyl chain. J Oleo Sci (2011) 0.75
New fluorescent probes applicable to aggregates of fluorocarbon surfactants. J Oleo Sci (2007) 0.75
Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia. J Int Med Res (2014) 0.75
Aggregate formation in oil and adsorption at oil/water interface: thermodynamics and its application to the oleyl alcohol system. J Colloid Interface Sci (2004) 0.75
Dissymmetric gemini surfactants generated by disulfide exchange in mixed micelles. J Oleo Sci (2010) 0.75
Aqueous solution properties of disulfide-linked fluorinated gemini and cleaved monomeric thiol surfactants. J Oleo Sci (2011) 0.75
[Biguanide]. Nihon Rinsho (2015) 0.75
Micelle-Vesicle Transition by Cleavage of Disulfide Spacer Chain for Gemini Surfactant in Didodecyldimethylammonium Chloride Aqueous Solutions. J Oleo Sci (2015) 0.75
The unusual micelle micropolarity of partially fluorinated gemini surfactants sensed by pyrene fluorescence. Langmuir (2006) 0.75
Generation of fluorocarbon and hydrocarbon hybrid gemini surfactants controlled by micellar miscibility. J Oleo Sci (2013) 0.75
Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes. Endocr J (2014) 0.75
Spontaneous vesicle formation of single chain and double chain cationic surfactant mixtures. J Phys Chem B (2007) 0.75
Effect of amino acid surfactants on phase transition of poly(N-isopropylacrylamide) gel. J Colloid Interface Sci (2003) 0.75
Self-assembly of amphiphilic molecules in droplet compartments: an approach toward discrete submicrometer-sized one-dimensional structures. Angew Chem Int Ed Engl (2012) 0.75
Effect of the α-glucosidase inhibitor miglitol on the glucose profile in Japanese type 2 diabetic patients receiving multiple daily insulin injections. Endocr J (2012) 0.75
Appearance of pure fluorocarbon micelles surveyed by fluorescence quenching of amphiphilic quinoline derivatives in fluorocarbon and hydrocarbon surfactant mixtures. Langmuir (2004) 0.75
Solubilization of genistein by caseinate micellar system. J Oleo Sci (2014) 0.75
Aqueous solution properties of disulfide linked gemini and cleaved monomeric thiol surfactants. J Oleo Sci (2008) 0.75